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Abstract 
    
Cannabinoids can mimic the infarct-reducing effect of early ischemic preconditioning, delayed 
ischemic preconditioning and ischemic postconditioning against myocardial ischemia/reperfusion. 
They do this primarily through both CB1 and CB2 receptors. Cannabinoids are also involved in 
remote preconditioning of the heart. The cannabinoid receptor ligands also exhibit an antiapoptotic 
effect during ischemia/reperfusion of the heart. The acute cardioprotective effect of cannabinoids 
is mediated by activation of PKC, ERK1/2 and p38 kinase. The delayed cardioprotective effect of 
cannabinoid anandamide is mediated via stimulation of PI3K-Akt signaling pathway and 
enhancement of HSP-72 expression. The delayed cardioprotective effect of another cannabinoid, 
Δ9-THC, is associated with augmentation of NO-synthase expression but data on the involvement 
of NO-synthase in the acute cardioprotective effect of cannabinoids are contradictory. The KATP 
channel is involved in the synthetic cannabinoid HU-210-induced cardiac resistance to 
ischemia/reperfusion injury.  Cannabinoids inhibit Na-Ca+2 exchange via CB2 receptor activation 
that may also be related to the antiapoptotic and cardioprotective effects of cannabinoids. The 
cannabinoid receptor agonists should be considered as prospective group of compounds for 
creation of drugs that are able to protect the heart against ischemia/reperfusion injury in the 
clinical setting. 
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A Brief History of the Discovery of Endogenous Cannabinoid System 
 
The endogenous cannabinoid system has been discovered relatively recently. The central 
cannabinoid receptor (CB1) was discovered In 1990,  its structure was revealed when it was 
cloned.1 CB1 is coupled to Gi/o-protein and is widespread in the brain.1,2 CB1 was found in the 
myocardium of adult rats3,4 and mice.5 In 1993, a peripheral cannabinoid receptor (CB2) was 
identified and cloned.6 The CB2 receptor is also coupled to Gi/o-protein and is most abundant in 
spleen.7,8,9 This receptor was also found in neonatal rat cardiomyocytes10 and in the left ventricle 
of adult mice.5 Activation of both CB1 and CB2 receptors promotes inhibition of adenylyl cyclase 
and voltage-gated Ca2+ channels. They also activate mitogen-activated protein kinases (MAPK), 
and phospholipase C (PLC).2,9,11 Activation of both MAPK and PLC are associated with 
cardioprotection.   
 
In 1999, an orphan G-protein coupled receptor consisting of 319 amino acids was found in some 
human brain nuclei.12 This receptor was named “GRP55”. It was later established that GRP55 is 
also a cannabinoid receptor and is expressed in the brain stem, frontal cortex, striatum, 
hypothalamus, cerebellum and hippocampus.13 GPR55 was later found in peripheral organs such 
as adrenals, spleen, jejunum and ileum. Only trace quantity of GPR55 mRNA was found in other 
organs and none has been found in the heart.13 The GPR55 receptor is distinguished from other 
endogenous cannabinoid receptors by its differential affinity to CB ligands. It exhibits high affinity 
to CP55,940, anandamide, Δ9-tetrahydrocannabinol (Δ9-THC), palmitoylethanolamine, and HU-
210 but it has low affinity to the CB1 antagonist SR141716 and does not interact with the 
CB1/CB2 agonist WIN55,212-2.13 The GPR55 receptor couples to Gα13-protein but does not 
interact with Gi- and Gq-protein.13 Selective antagonists of GPR55 have not yet been synthesized 
so the regulatory function (if any) of GPR55 remains obscure.  
 
In 2003, Fride et al14 using CB1 receptor knockout mice obtained indirect evidence of the 
existence of a third (CB3) receptor. It is unique in that this receptor does not interact with the 
CB1/CB2 agonists WIN55,212-2, or CP55,940.14 The Kunos laboratory15,16 had also proposed the 
existence of another cannabinoid receptor in 1999. The receptor was present at the vascular 
endothelium and exhibited high affinity to the endogenous cannabinoid anandamide and 
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methanandamide (synthetic analogue of anandamide) but did not interact with other CB receptor 
agonists.16,17 This receptor can be inhibited by the CB1 receptor antagonist SR141716A but not by 
the CB2 receptor antagonist SR144528.16,17 This receptor was named “SR141716A-sensitive 
anandamide receptor" to distinguish it from CB1 receptors.16 In 2000, Di Marzo et al18 discovered 
yet another G-protein coupled anandamide receptor in the brain of CB1 knockout homozygotes 
mice. This receptor was insensitive to SR141716A and SR144528 and apparently was different 
from the SR141716A-sensitive anandamide receptor found by Kunos’s group.  
 
Kunos’s group discovered yet another Gi/o-protein-coupled endothelial receptor in 2003. This 
receptor exhibited a high affinity to the regioisomer of cannabidiol, abnormal cannabidiol.19,20 This 
receptor promoted endothelium-dependent vasodilation of isolated rat mesenteric arteries via 
opening of Ca2+-dependent K+ channel.19,20 This effect was abolished by the cannabidiol analog O-
1918 but not by CB1 and CB2 antagonists.19,20 Experiments on human umbilical vein endothelial 
cells showed that increase in outward K+ current, produced by abnormal cannabidiol, was blocked 
by KT-5823, an inhibitor of protein kinase G, or 1H-[1,2,4]oxadiazolo[4,3-a]quinoxaline-1-one 
(ODQ), an inhibitor of soluble guanylate cyclase.19 It has been also established that in endothelial 
cells abnormal cannabidiol activates extracellular signal-regulated kinase (ERK) and Akt kinase.20 
Abnormal cannabidiol-induced vasorelaxation was maintained after inhibition of NO-synthase by 
L-NAME or in combination with vanilloid VR1 receptor antagonist capsazepine.20 The authors 
concluded that a Ca2+-activated K+ current in endothelial cells is potentiated by activation of a Gi/o-
coupled receptor distinct from CB1 or CB2. This receptor signals through cGMP and protein 
kinase G to increase the K+ channel availability or its sensitivity to voltage and/or Ca2+.19  
 
Thus to date, the existence of at least five cannabinoid receptors has been confirmed: CB1, CB2, 
GPR55, anandamide receptor (there may actually be two distinct anandamide receptors) and 
cannabidiol receptor. It is likely that more cannabinoid receptors have yet to be discovered.  
 
Devane et al. discovered the first endogenous cannabinoid N-arachidonylethanolamine 
(anandamide).21 We (Mechoulam group) subsequently found that 2-arachidonyl glycerol (2-AG) is 
also an endogenous cannabinoid22 and in 2001, we found endocannabinoid 2-arachidonyl glyceryl 
ether (noladin ether).23 Another endocannabinoid, oleamide, was identified in 2004.24 This was 
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followed by a discovery of N-arachidonoyl-L-serine25 and RVD-Hemopressin.26 A list of the 
currently available cannabinoid ligands and their properties are presented in Table 1. 
 
 
Effect of CB1 and CB2 receptors on Cardiac Tolerance to Ischemia/Reperfusion Injury 
 
The ability of cannabinoids to increase the heart’s tolerance to the pathogenic impact of 
ischemia/reperfusion has now been demonstrated in a number of studies27,28,29,30,31,32,33,34 are 
summarized in Table 2 of our review. The infarct sparing effect of these compounds has been 
shown both in vivo5,27,28,34,35 and ex vivo.29,30,31,32,33,35 These investigators suggest that the heart 
represents a direct target of exogenous cannabinoids in the implementation of their 
cardioprotective effects.29,30,31,32,33,35 We (Maslov group) found that treatment with CB1/CB2 
receptor agonist HU-210 prior to ischemia promotes a decrease in the fraction of the ischemic zone 
that is infarcted (IS/AAR ratio) in vivo.28,34 We have found that infarct sparing effect of HU-210 
(0.1 mg/kg) in vivo disappeared after blocking CB1 receptor with SR141716A but was maintained 
after CB2 receptor blockade with SR14452829 or neural ganglion inhibition by hexamethonium.37 
Addition of HU-210 to the perfusion solution prior to 45 min global ischemia and 30 min 
reperfusion of isolated rat heart promoted a decrease in the amount of creatine kinase (CK) leaked 
into the coronary effluent.29 The selective CB1 agonist ACPA exhibited a similar effect in vitro 
whilst the selective CB2 agonist JWH 133, anandamide and methanandamide had no effect on 
cardiac tolerance to ischemia/reperfusion injury in vitro.37,38 However, our recent in vivo 
experiments showed that JWH133 at high dose (20 mg/kg intravenously) was able to reduce the 
IS/AAR ratio.39 Pretreatment with the CB2 receptor antagonist AM630 abolished infarct reducing 
effect of JWH133. These results indicate the involvement of CB2 receptors as well in the infarct 
limiting effect of JWH133. Thus, cardioprotective effect of cannabinoid receptors is well 
established but the data on the role of particular cannabinoid receptors are contradictory and need 
to be further investigated. 
 
Can Cannabinoids Postconditioning the Heart? 
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A major clinical indication for a cardioprotectants is acute myocardial infarction when a coronary 
artery is suddenly blocked with a thrombus. Emergency recanalization of the artery is the 
treatment of choice but, unfortunately, this can seldom be accomplished before a significant 
fraction of the ischemic myocardium is irreversibly injured. A series of very brief 
reperfusion/occlusion cycles at the onset of reperfusion (termed ischemic postconditioning) offers 
protection to the heart similar to that with preconditioning.40 Ischemic postconditioning in the 
clinical setting is difficult however and there is a need for a pharmacological substitute. Two 
studies related to cannabinoids have addressed this. Defer et al27 reported that a 5 min injection of 
the selective CB2 agonist JWH133 (3 mg/kg) at the end of 1 h coronary artery occlusion decreased 
the IS/AAR ratio in wild type mice. This protection was not observed in CB2 receptor knockout 
mice.27 In our experiments, 5 min intravenous administration of the CB1/CB2 receptor agonist 
HU-210 (0.1 mg/kg) before reperfusion in isolated rat hearts reduced the IS/AAR ratio by half.41 
The above results imply that stimulation of CB2 receptors by exogenous cannabinoids do promote 
an anti-infarct effect when administered just prior to reperfusion both in vivo and ex vivo. Cleary, 
more postconditioning studies are needed. 
 
Cannabinoids and the No-Reflow phenomenon 
 
Another consequence of ischemia/reperfusion is decreased coronary reflow in the reperfused 
myocardium (the no-reflow phenomenon).  Ischemic preconditioning improves reflow and the 
endogenous cannabinoids palmitoylethanolamide (PEA) and 2-AG mimicked the vasoprotective 
effect.42 Gonzalez et al published novel results of experiments carried out on isolated perfused rat 
heart.43 The investigators administered the CB1 and CB2 receptor agonist WIN 55,212-2 (1 
mg/kg) intraperitoneally and then removed the hearts and performed global ischemia and 
reperfusion of the hearts ex vivo. They found that WIN 55,212-2 had no effect on the left 
ventricular developed pressure and end-diastolic pressure but significantly attenuated the rise in 
coronary resistance during reperfusion.  The reduction of coronary resistance was interpreted by 
the authors as a vasoprotective effect.43 The vasoprotective effect was unaffected by the blockade 
of CB1 receptors but disappeared after inhibition of CB2 receptors.43 They concluded that 
exogenous cannabinoids prevent injury to the endothelium of coronary arteries evoked by 
ischemia/reperfusion via activation of CB2 receptors.  
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Cannabinoids and Remote Ischemic Preconditioning 
 
Gho and colleagues found that a preliminary 15 min occlusion of mesenteric arteries increases 
cardiac tolerance to ischemia/reperfusion with a reduced IS/AAR ratio.44 Fifteen minutes ischemia 
of the left kidney also decreased the IS/AAR following coronary artery occlusion/reperfusion.44 
This cardioprotective phenomenon was named “remote ischemic preconditioning”.44,45,46 
Interestingly, CB2 (but not CB1) receptor inhibition, eliminated the cardioprotective and 
antiarrhythmic effect of remote preconditioning with intestine ischemia in rats.47 Because the 
authors did not determine the level of cannabinoids in the blood, it was not clear whether 
endogenous cannabinoids were the circulating cardioprotective factor or whether they only acted 
as intermediaries between cardiomyocytes and an unidentified circulating factor. Nevertheless, 
these data indicate that endogenous cannabinoids are involved at some level in the infarct limiting 
effect of remote ischemic preconditioning. No data are yet available whether cannabinoids 
participate in remote preconditioning with limb ischemia. 
 
Controversy as to which cannabinoid receptors protect the heart 
 
In experiments with isolated rat hearts Underdown et al36 have found that anandamide (1 μM) and 
methanandamide (1 μM) decrease the IS/AAR ratio after 30 min global ischemia and 1 h 
reperfusion by 2.5-fold. Because, the CB1/CB2 receptor agonist HU-210 (1 μM) did not exert a 
similar effect, they concluded that neither CB1 nor CB2 was the target. Accordingly, the authors 
did not observe an infarct-reducing effect of the selective CB1 receptor agonist ACPA (1 μM) or 
the selective CB2 receptor agonist JWH-133 (1 μM).36 The beneficial effect of anandamide was 
also not affected by the blockade of CB1 or CB2 receptors. The authors concluded that the 
cardioprotective effect of anandamide is dependent upon a cannabinoid receptor different from 
CB1 or CB2.36  
 
The above work contradicts to our data where we (Maslov group) were able to show 
cardioprotective effect of HU-210 at the concentration of 0.1 μM and ACPA at the concentration 
of 1.0 μM.29,33,37,38 We suggest that this discrepancy is due to the differences in the experimental 
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protocol. Underdown and colleagues administered HU-210 and ACPA from 5 min before ischemia 
until the end of reperfusion.36 In contrast, we mimicked the phenomenon of preconditioning by 
perfusion of the hearts with HU-210 and ACPA for 10 min followed by 10 min washout prior to 
ischemia.29,33,37 Furthermore, Underdown et al used a rather high concentration of HU-210 (1 
μM).36 According to our data, perfusion of hearts with HU-210 at the concentration of 0.1 μM for 
10 min before ischemia gives maximal cardioprotective effect.48 Further increase of HU-210 
concentration did not enhance its protective effect. HU-210 at high concentration induced a 
marked bradycardia and decreased hemodynamic function of the isolated perfused rat heart.49 
 
One possible explanation of these differing conclusions is that the receptors could have developed 
tolerance to the high concentration of HU-210 causing the protective effect to wane during its 
prolonged exposure. Another is that HU-210 may protect through a process termed homesis. That 
is, HU-210 may actually have a noxious effect on the heart which happens to trigger a protective 
adaptation after its removal, much like ischemia does in ischemic preconditioning.  If that is the 
case, then its continued presence during ischemia might actually be detrimental. In ischemic 
preconditioning the protective signals can be divided into triggers and mediators. The triggers start 
the protective cascade prior to ischemia and their signal does not have to be sustained. An example 
would be a 5 min pulse of adenosine, opioid or bradykinin which puts the heart into a 
preconditioned state that lasts for about an hour. Mediators exert their protection at the time of 
reperfusion and protection relies on their continuous signal during reperfusion. An example of a 
mediator would be the activation of ERK or inhibition of GSK3β which act to inhibit 
mitochondrial permeability transition pore (MPTP) formation during reperfusion.50 Triggers have 
to be administered prior to ischemia while mediators can usually be started just prior to reperfusion 
which allows their use in the setting of acute myocardial infarction. The above studies indicate that 
the schedule and dose are important and these clearly need further exploration. 
 
In the experiments on isolated rat heart, the Maslov group induced global ischemia (45 min) and 
reperfusion (30 min). Pretreatment of the hearts with a solution containing cannabinoid HU-210 
(0.1 or 1.0 μM) for 10 min followed by 10 min washout resulted in a two-fold decrease in creatine 
kinase activity in the coronary effluent.48 The cardioprotective effect of this compound remained 
unchanged after NO synthase inhibition, which bracketed the HU-210 infusion. HU-210 reduced 
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cAMP level in the myocardium by two-fold during reperfusion but did not affect this parameter 
before or during ischemia. This cannabinoid also had no effect on the level of cGMP in the 
myocardium.48 Thus, the cardioprotective effect of HU-210 is accompanied with a decrease in 
cAMP level in the myocardium during reperfusion whilst cGMP and NO synthase are not involved 
in HU-210 triggering this effect ex vivo. 
 
Another study was performed on mice with in situ coronary artery occlusion/reperfusion revealed 
that injection of the CB1/CB2 receptor agonist WIN 55,212-2 thirty minutes prior to ischemia 
promotes a decrease in the IS/AAR ratio. This effect was maintained after the blockade of CB1 
receptor by AM215 but disappeared after perfusing the heart with the selective CB2 antagonist 
AM630.35 They concluded that the CB2 receptor was the protective one. AM630 produced a slight 
but significant (P<0.05) increase in the IS/AAR ratio compared with the vehicle alone whilst 
AM215 had no effect on the IS/AAR index. Ideally the blocker should have no effect on the injury 
to the untreated heart. Perhaps, AM630 aggravates ischemia/reperfusion injury independently of 
its binding to CB2 receptor and the CB2 receptor was not actually involved. But that does not 
explain the lack of effect of AM215.  Infarct-reducing effect of WIN 55,212-2 was accompanied 
by a decrease in the activity of myeloperoxidase in cardiac tissue.35 It is known that this enzyme is 
an indicator of neutrophils invasion in myocardial tissue during ischemia/reperfusion injury of the 
heart.51 The authors concluded that CB2 receptor activation protects via a decrease in neutrophil 
accumulation in myocardium. It is possible that protection was associated with other mechanisms 
and the decreased neutrophil content simply reflected less tissue necrosis. Cause and effect is 
difficult to determine in this type of experiment, however, the fact that WIN 55,212-2 is protective 
in neutrophil- free isolated hearts would argue for the second hypothesis.43 
 
The above data are strongly supported by the results of Wang et al5 who also used mice.  Hearts 
were subjected to either 30 min coronary artery occlusion and 24 h reperfusion or 24 h of 
continuous occlusion. The highly selective CB2 agonist HU-308 was administered 
intraperitoneally (2 mg/kg) 2 h prior to ischemia and decreased the IS/AAR ratio 2-fold in the 
reperfused group. This effect of HU-308 was reversed by pretreatment with the CB2 selective 
antagonist AM630.5 Perhaps, mouse hearts are fundamentally different that rat hearts. In the 
continuous occlusion group, the IS/AAR ratio was also decreased 1.5-fold. This last result is the 
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most surprising because, according to a widespread opinion, it is impossible to achieve a decrease 
in infarct size without reperfusion in a species that has negligible coronary collateral blood flow 
like the mouse. In this case, pharmacological agents or a preconditioning protocol can only delay 
cell death.52,53,54 The time required for ischemia to kill all of the tissue in the ischemic zone in 
experimental animals fluctuates between 3 – 6 h.52,53,54,55 Accordingly, after 6 h of ischemia, 
reperfusion does not promote a decrease in infarct size.53,55 These data are also confirmed by the 
clinical observations.56 A cannabinoid may delay cell death for an hour or two but it is difficult to 
imagine that it could maintain viability for 24 h in the absence of blood flow. The results of 
permanent occlusion shown by Wang’s group are difficult to explain.  
 
CB2 protection has been reported in rats as well. Vogel’s group found that Δ9-THC could increase 
tolerance of rat neonatal cardiomyocytes to hypoxia.10 Hypoxia was produced by incubating the 
cardiomyocytes in an argon-filled chamber with a glucose-free medium for 60 min.10 The 
cannabinoid Δ9-THC was added to the medium 24 h before the hypoxia exposure. Hypoxia evoked 
lactate dehydrogenase (LDH) leakage from cardiomyocytes indicating cardiac cell necrosis. Δ9-
THC reduced LDH release. When the selective CB2 receptor antagonist SR144528 was added 1 h 
before incubation with Δ9-THC, protection effect was absent.10 Since the selective CB1 receptor 
antagonist SR141716 did not attenuate the cytoprotective effect of Δ9-THC, they concluded that 
the CB2 receptor caused the protection. It has been reported that neonatal cardiomyocytes only 
express CB2 receptors10 which is consistent with the above observation.  
 
Another study examined the interaction between CB1, CB2 receptors and the mechanism of their 
cardioprotective effects.30  Isolated perfused rat hearts were subjected to 2 h low-flow ischemia 
(flow rate 0.6 ml/min) and 20 min reperfusion. Necrosis was estimated by measuring of LDH and 
creatine kinase (CK) levels in the coronary effluent.  One of the following (CB1/CB2/GRP55 
receptor agonist anandamide, the selective GPR55 agonist PEA or the CB1 receptor agonist 2-AG) 
was added to the perfusion solution 15 min before ischemia: and perfused throughout the ischemic 
period. PEA and 2-AG decreased LDH and CK levels in coronary effluent whilst anandamide had 
no effect on these parameters. The CB2 receptor antagonist SR144528 reversed the cytoprotective 
effect of PEA and 2-AG. The CB1 receptor antagonist SR141716A abolished the cardioprotective 
effect of 2-AG. The authors concluded that cardioprotection may be achieved via stimulation of 
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both CB1 and CB2 receptors. It should be noted however, that this conclusion was challenged 
when it was later found that PEA has no significant affinity for either CB1 or CB2. In another 
publication from this group, isolated perfused rat hearts were subjected to 90 min low-flow 
ischemia and 60 min reperfusion. This time more selective cannabinoid agonists (ACEA and 
JWH015) were present in the perfusion solution for 5 min before ischemia and throughout the 
ischemic period.31 Both the selective CB1 receptor agonist ACEA (50 nM) and the selective CB2 
receptor agonist JWH015 (50 nM) decreased the IS/AAR ratio30,31 again supporting the hypothesis 
that both CB1 and CB2 can be involved in the cardioprotective effects of cannabinoids. Interesting 
that the infarct reducing effect of ACEA was not observed after inhibition of NO synthase by NG-
nitro-L-arginine. However, this NO synthase inhibitor did not attenuate the cardioprotective effect 
of JWH01531 suggesting that the cardioprotective effect of CB1, but not CB2 receptor stimulation, 
is mediated by endothelial NO synthase.  
 
Both CB1 and CB2 receptors are present in the heart 
 
Some of the data presented above contradict our results that the infarct reducing effect of HU-210 
depended on CB1, but not CB2 receptor stimulation.29,33  The expression of these receptors may 
differ among the various models. Z. Vogel’s group found that the CB1 receptor is absent in 
cardiomyocytes of newborn rats10 indicating that the age of animals plays an important role. 
Message for the CB1 receptor has been reported to be in human myocardium.7  Wagner et al. 
found evidence of CB1 receptors in myocardium of adult rats.4 Two years later, they confirmed an 
existence of this receptor in the adult rat heart by immunohistochemistry.17  However, they could 
not find CB2 receptors in the myocardium of adult rats. Brown et al reported that mRNA for the 
CB2 receptor could not be found in the myocardium of adult rats.62 In contrast, a Canadian group 
of investigators reported that mRNA and proteins of both CB1 and CB2 receptors are present in 
the heart of adult rats.31 They have shown that CB1 receptors are localized almost exclusively on 
the arterial and capillary endothelial cells in the heart, whereas CB2 receptors are expressed in 
cardiomyocytes and endothelial cells of larger arteries.31 Recently, both CB1 and CB2 receptors 
were found in the tissue of left ventricle of mice by Western blot analysis.5  
 
12 
 
Much of the differences among the above studies may well reflect differences in the various 
models of ischemia/reperfusion: in situ vs. isolated hearts, whole hearts vs. isolated myocytes, 
mice vs. rats. The dose and schedules of drug administration also vary widely among the studies 
ranging from pretreatment with the ligands to acute administration just prior to ischemia. In some 
studies the drug was withdrawn prior to ischemia and in others it was present during ischemia. In 
in vivo studies, the drug probably persisted during reperfusion. It is therefore not surprising that the 
results will be discrepant. While the experiments on receptor subtypes in myocardium are 
contradictory, we propose that the weight of evidence supports the hypothesis that under certain 
circumstances, cannabinoids can protect the hearts of adult animals through occupancy of CB1 and 
CB2 receptors.  
 
Delayed preconditioning 
 
Protection from ischemic preconditioning wanes after an hour or two but a second window of 
prolonged protection appears 24 h later.57 This phenomenon was termed “delayed” ischemic 
preconditioning. The protection involves increased myocardial NO production via expression of 
inducible NO-synthase (INOS).58 Prolonged exposure to Δ9-THC mimics delayed preconditioning 
by increasing INOS content 4-fold.10 We (Zhang group) have recently obtained data showing that 
the endogenous cannabinoid anandamide can mimic delayed ischemic preconditioning.59 We 
found that anandamide, administered to rats intravenously (1 mg/kg), induced expression of 
HSP72, which peaked 24 h later. Induction of HSP72 is also a prominent feature of delayed 
ischemic preconditioning.57,60 We induced 30 min LAD occlusion followed by 120-min 
reperfusion in vivo 24 h after the administration of anandamide, and found a 2-fold decrease in the 
IS/AAR ratio. This cardioprotective effect was reversed by pretreatment with the CB2 receptor 
antagonist AM630 but not with the CB1 receptor antagonist AM251 indicatings a CB2 effect. 
Anandamide’s elevation in HSP72 was also eliminated by AM630, but not AM251.  
 
It was recently reported that pretreatment of mice intraperitoneally with an ultra-low dose (2 
μg/kg) of Δ9-THC 48 or 24 h prior to coronary artery occlusion is cardioprotective.61 They showed 
that this cannabinoid decreases infarct size, elevates fractional shortening, reduces troponin T 
leakage to the blood and decreases the accumulation of neutrophils to the infarct area. 
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Unfortunately, the authors did not measure area at risk in these hearts, which reduces the accuracy 
of estimation of the actual extent of the infarct size reduction induced by Δ9-THC. The current data 
indicate, however, that both anandamide and Δ9-THC can mimic delayed preconditioning in the 
intact heart. 
 
Cannabinoids and Apoptosis  
 
Recently, we (Zhang group) found that intravenous administration of the CB2 receptor agonist 
JWH133 (20 mg/kg) in rats prior to coronary artery occlusion and reperfusion decreases the 
apoptotic index in the area at risk 3-fold.39 Pretreatment with the CB2 receptor antagonist AM630 
abolished antiapoptotic effect of JWH133 implicating CB2 receptors. We established that 
ischemia/reperfusion increase caspase 3 and caspase 9 in the myocardium. Injection of JWH133 
promoted a decreased caspase 3 approximately 5-fold and caspase 9 12-fold.39 It is well known 
that opening of MPTP is a trigger of apoptosis.63,64 Opening of this pore reduces potential on the 
inner mitochondrial membrane (Δψ) and releases cytochrome C and other apoptosis-inducing 
factors from the intermembrane space into the cytosol.63,64 Cytochrome C together with APAF-1 
(apoptosis protease activating factor), procaspase-9 and ATP form a supramolecular complex 
called the apoptosome.64 Apoptosome catalyzes the proteolysis of procaspase-9, which results in 
transformation of procaspases to their active forms. Caspases catalyze the cleavage of other 
proteins, which ultimately leads to apoptosis.  In the in vivo experiments on rats, we found that the 
CB2 receptor agonist JWH133 resulted in a 2.5-fold decrease in cytochrome C level and inhibited 
the fall in Δψ. Blocking CB2 with AM630 eliminated these effects.39 We propose that the 
antiapoptotic effect of JWH133 is an outcome of MPTP inhibition via CB2 receptor stimulation.  
 
Signaling Pathways of Cardioprotective Effect of Exogenous Cannabinoids  
 
Oxidative stress is thought to play an important role in the pathogenesis of ischemia/reperfusion-
induced heart injury.65,66 Defer et al27 tested whether cannabinoids can enhance resistance of 
cardiomyocytes to the detrimental effects of oxidative stress. Cardiomyocytes of wild-type 
(control) and CB2-/- mice were incubated for 12 h in the presence of H2O2 which induced death of 
approximately 90% of cells in both control and knockout groups. The selective CB2 agonist 
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JWH133 (1 μM) increased cell survival during oxidative stress 5-fold. However, the protective 
effect was not observed in the presence of the selective CB2 antagonist АМ630 (5 μM).27 These 
data suggest that the cardioprotective effect of cannabinoids may be the result of an increased 
tolerance of the cardiomyocyte to oxidative stress. Current thinking is that preconditioning protects 
by preventing oxidative stress-induced opening of lethal MPTP in the heart’s mitochondria at 
reperfusion67 and the Defner et al. study suggests that cannabinoids protect through a similar 
mechanism. 
 
A number of studies have shown that PKC, p38MAPK , MEK1/2 (mitogen-activated protein 
kinase) - ERK1/2 and PI3K (phosphatidylinositol 3-kinase) - Akt pathways are involved in the 
mechanisms of protection of ischemic preconditioning and its pharmacological mimetics.68,69,70 
Lépicier et al. investigated the signaling mechanism of the cytoprotective effect of PEA using a 
model of low-flow ischemia and reperfusion on isolated rat heart.30 Pretreatment of the hearts with 
the PKC inhibitor chelerythrine, the MEK1/2 inhibitor PD98059 or the p38MAPK blocker 
SB203580 reversed the cardioprotective effect of PEA.30 Furthermore, they showed that this 
endogenous cannabinoid induced phosphorylation of ERK1/2.30 These data are consistent with our 
(Maslov group) study, which indicated that PKC is involved in the cardioprotective effect of HU-
210.29,33,37 One hour after injection of anandamide, which is able to mimic the effect of delayed 
ischemic preconditioning, resulted in an 8-fold increase in Akt phosphorylation but 24 h later Akt 
phosphorylation had returned to its control value.59 Pretreatment of isolated rat hearts with the 
PI3K inhibitor wortmannin, Akt inhibitor MK-2206 and the CB2 receptor antagonist AM630 all 
attenuated early anandamide- induced phosphorylation of Akt and delayed expression of HSP72.59 
More recently, we have found that JWH133 during in vivo ischemia/reperfusion promoted Akt 
phosphorylation (Figure 1) and had an anti-infarct and anti-apoptotic effect in rat hearts. 
Pretreatment with wortmannin abolished the protection showing that Akt had a functional role in 
the protection.39  
 
Recent data have suggested that an alteration in pro-inflammatory cytokines may also be involved 
in the cardioprotective effect of cannabinoids. This study revealed that 30 min coronary artery 
occlusion and 24 h reperfusion or 24 h permanent occlusion evoked a 1.5-fold increase in the level 
of tumor necrosis factor α (TNF-α) in the blood of mice.5 Intraperitoneal injection of the CB2 
15 
 
agonist HU-308 prior to coronary artery occlusion in mice abolished the rise in TNF-α. However, 
pretreatment with the CB2 receptor antagonist AM630 reversed HU-308’s effect.5 TNF-α is 
known to be involved in the pathogenesis of inflammatory heart damage induced by 
ischemia/reperfusion.71 These data support the hypothesis that a decrease in TNF-α is involved in 
HU-308-induced protection.  
 
The above-mentioned data suggest that NO-synthase could be involved in the cardioprotective 
effects of cannabinoids. Let’s try to compare and analyze these data. It was established that the 
NO-synthase inhibitor L-NAME abolished delayed cardioprotective effect of Δ9-THC.10 
Furthermore, it was found out that Δ9-THC increased NO production 3 fold and enhanced 
expression of INOS 24 h after the pretreatment with Δ9-THC.10 The early infarct-reducing effect in 
isolated rat heart of the selective CB1 agonist ACEA was reversed by co-infusing the NO-synthase 
inhibitor NG-nitro-L-arginine. However, this NO-synthase inhibitor did not affect cardioprotective 
effect of the selective CB2 agonist JWH015.31 We (Maslov group) also found that the inhibition of 
NO-synthase with L-NAME did not affect the HU-210-induced increase in cardiac tolerance to 
ischemia and reperfusion in vivo37 or ex vivo.33 Thus, we conclude that NO-synthase is involved in 
cannabinoid- induced delayed preconditioning and is suggested to be involved in the CB1 induced 
early preconditioning but is clearly not involved in CB2-induced early preconditioning. 
 
Opening of the KATP channel is an important step in the signaling of ischemic preconditioning.72 
We (Maslov group) have found that 10 min perfusion of isolated rat heart with buffer containing 
HU-210 (100 nmol/L) 20 min prior to global ischemia is able to decrease CK release during 
reperfusion.33 Pretreatment with the KATP channel blocker glibenclamide abolished the 
cardioprotective effect of HU-210. This indicates that the KATP channel is also involved in 
cannabinoid- induced cardioprotection. 
 
It has been revealed that an enhancement of Na+/Ca2+ exchange (NCX) during 
ischemia/reperfusion aggravates ischemia/reperfusion heart injury.73 Not surprisingly, inhibition of 
NCX during ischemia is highly protective.73,74 Recently, in experiments on isolated rat 
cardiomyocytes, we (Zhang group) have established that anandamide (1-100 nM) dose-
dependently suppressed the increase in NCX.75 Furthermore, anandamide (100 nM) significantly 
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attenuated the increase in [Ca2+]i during simulated ischemia. Pretreatment of the cardiomyocytes 
with the CB1 receptor antagonist AM251 failed to inhibit the effects of anandamide on NCX and 
[Ca2+]i in these experiments. Meanwhile the CB2 receptor antagonist AM630 eliminated the 
effects of anandamide on NCX and [Ca2+]i during simulated ischemia. The CB2 receptor agonist 
JWH133 (100 nM) also suppresses the increase in NCX and [Ca2+]i during simulated ischemia. In 
addition, pretreatment of the cells with the Gi/o inhibitor pertussis toxin abolished the above-
mentioned effects of anandamide and JWH133.75 These findings indicate that activation of Gi/o-
protein coupled CB2 receptor inhibits NCX and prevents Ca2+ overload. It is well known that Ca2+ 
is one of the triggers of MPTP opening64 and represents a major source or reperfusion injury in the 
heart.73 These results imply that cannabinoid- induced NCX inhibition during ischemia/reperfusion 
may also contribute to the protection against ischemia/reperfusion.  
 
Concluding Remarks 
 
In summary, current data indicate that cannabinoids mimic the infarct reducing effect of early 
preconditioning, postconditioning, and delayed preconditioning and are involved in at least some 
forms of remote preconditioning of the heart. Cannabinoids also exhibit an antiapoptotic effect. 
The acute cardioprotective effect of cannabinoids can be mediated via activation of PKC, ERK1/2 
and p38 kinase. The delayed cardioprotective effect of anandamide is mediated via stimulation of 
PI3K-Akt signaling pathway and enhancement of HSP-72 expression. As in preconditioning, the 
KATP channel is also involved in the cardioprotective effect of cannabinoids. The delayed 
cardioprotective effect induced by a cannabinoid Δ9-THC is mediated via enhancement of 
inducible NO-synthase expression. However, unlike the case with ischemic preconditioning, data 
on the involvement of NO-synthase in the acute cardioprotective effect of cannabinoids are 
contradictory. Anandamide and JWH133 inhibit NCX via CB2 receptor activation that may be 
related to the antiapoptotic effect of cannabinoids. In conclusion, agonists of CB receptors can be 
considered as an important group of chemical compounds that should be further explored for the 
creation of drugs that prevent injury from ischemia/reperfusion in the clinical setting.  
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Tables 
 
Table 1. A list of cannabinoid ligands and their properties. 
 
Cannabinoid Ligand                                     Properties         
2-AG (2-Arachidonoylglycerol)                   Endogenous CB1 agonist 
Abnormal cannabidiol                                  Selective GPR55 agonist 
ACPA (Arachidonylcyclopropylamide)       Selective CB1 agonist 
ACEA (Arachidonyl-2'-chloroethylamide)   Highly selective CB1 agonist (Ki =1.4 nM) with 1400-fold 
                                                                      selectivity over CB2                                                                                                                                                                                                                                         
CP55,940:                                                    Potent, non-selective cannabinoid receptor agonist                                                                       
AM630                                                         CB2 antagonist/inverse agonist (Ki = 31.2 nM) that displays 
                                                                   165-fold selectivity over CB1 receptors.                                                                      
AM 251                                                       Potent and selective CB1 antagonist/inverse agonist. Structurally 
                                                                   related to SR141716A  (Ki value of 7.49 nM at CB 1 and 300 fold 
                                                                   less sensitive at CB2)                                                                     . 
Anandamide                                                GPR55, CB1 and CB2 agonist 
Δ9-tetrahydrocannabinol (Δ9-THC):           Potent CB1 and CB2 agonist that naturally occurs in cannabis.                                                                     
HU-210                                                       Highly potent CB1 and CB2 agonist 
HU-308                                                       Highly selective CB2 agonist 
JWH 133                                                     Potent CB2 selective agonist (Ki = 3.4 nM) 
JWH 015                                                     CB2 selective agonist 
Methanandamide                                        CB1 selective agonist (Ki = 20 and 815 nM for CB1 and CB2, 
                                                                   respectively). 
O-1918                                                        Putative endothelial anandamide receptor antagonist distinct 
                                                                  from CB1 or CB2 receptors. Inhibits vasodilation and cell migration                                                                             
induced by abnormal-cannabidiol.                                                                   
Palmitoylethanolamine (PEA):                  GPR119  and  GPR55 agonist 
SR141716A                                                Selective CB1 antagonist 
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SR144528                                                  Potent and highly selective CB2 antagonist/inverse agonist, 
                                                                  (Ki of 0.6nM at CB2 and 400 nM at CB1)                                                                    
WIN55,212-2                                              Selective CB2 agonist (Ki values are 62.3  and 3.3 nM for human  
                                                                    cloned CB1 and CB2 receptors, respectively)  
 
 
  
Table 2. Cannabinoid receptor agonists reported to protect the heart against ischemia/reperfusion injury.  
Cannabinoid                                                   
 
CB receptors
activated  
Experiment 
conditions  
Dose (or concentration) 
and schedule 
Effect CB receptor 
involved in 
the effect 
Signaling   
pathways 
Reference 
HU-210                                                           CB1/CB2 In vivo               0.1 mg/kg  Infarct-reduction CB1 PKC    
HU-210 CB1/CB2 In vivo 0.03-0.1 mg/kg  at 
reperfusion 
Infarct-reduction No data No data  
HU-210 CB1/CB2 In vitro 0.1 μM pretreatment Decrease in enzyme 
release 
CB1 PKC, KATP    
JWH133    CB2     In vivo 20 mg/kg pretreatment Infarct-reduction, 
suppression of apoptosis  
CB2 PI3K/Akt  
JWH133 CB2    In vivo    3 mg/kg at reperfusion  Infarct reduction CB2 No data  
WIN 55.212-2                                                                     CB1/CB2 In vivo 1 mg/kg Prevention of no-reflow CB2   No data  
WIN 55.212-2 CB1/CB2 In vivo 3.5 mg/kg pretreatment Infarct reduction CB2 No data  
HU-308       CB2   In vivo 2 mg/kg pretreatment Infarct reduction CB2 No data  
Anandamide     CB1/CB2 In vivo 1 mg/kg pretreatment Infarct reduction, 
suppression of apoptosis 
CB2 PI3K/Akt  
Anandamide     CB1/CB2 Ex vivo 1 μM pretreatment Infarct reduction No data No data  
Δ9-THC         CB1/CB2 In vivo 0.002 mg/kg Infarct reduction 24hr 
after treatment 
No data No data  
Δ9-THC                                                                                      CB1/CB2 In Vitro 10 μM pretreatment Decrease in enzyme 
release 
CB2   No data  
ACPA                      CB1                     Ex vivo  1 μM pretreatment     Decrease in enzyme 
release 
  No data No data  
Methanandamide                                                     CB1/CB2 Ex vivo 1 μM pretreatment Infarct reduction No data      No data  
PEA                        GPR55 Ex vivo 0.3 μM pretreatment Decrease in enzyme 
release 
CB2 p38 MAPK, 
PKC, MEK1/2, 
ERK/12 
 
2-AG                                                                         CB1/CB2 Ex vivo 0.3 μM Decrease in enzyme 
release 
CB2 No data  
ACEA                   CB1     Ex vivo 0.05 μM Decrease in enzyme 
release 
No data NO-synthase  
JWH015    CB2 Ex vivo 0.05 μM Decrease in enzyme 
release 
No data No data  
 
KC, protein kinase C; PI3K, phosphatidylinositol-3-kinase; Akt, kinase isolated from AKR thymoma cell line; p38 MAPK, p38 mitogen activated 
kinase; MEK1/2, mitogen-activated protein kinase kinase; ERK1/2, extracellular signal-regulated kinase; PKC, protein kinase C; NO, nitric oxide; 
CB, cannabinoid; KATP, ATP-sensitive K
+ channel.  Experiment conditions: in vivo, experiments on isolated cells; ex vivo, experiments on isolated 
heart; in vivo, experiments on a whole animal. “No data” means that the data on this particular subject either absent or controversial.  
